- Home
- GBTG vs AKRO Comparison
GBTG vs AKRO Comparison
Compare GBTG & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBTG
- AKRO
- Stock Information
- Founded
- GBTG 2014
- AKRO 2017
- Country
- GBTG United States
- AKRO United States
- Employees
- GBTG N/A
- AKRO N/A
- Industry
- GBTG Computer Software: Prepackaged Software
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- GBTG Technology
- AKRO Health Care
- Exchange
- GBTG Nasdaq
- AKRO Nasdaq
- Market Cap
- GBTG 4.3B
- AKRO 3.6B
- IPO Year
- GBTG N/A
- AKRO 2019
- Fundamental
- Price
- GBTG $8.24
- AKRO $47.47
- Analyst Decision
- GBTG Strong Buy
- AKRO Strong Buy
- Analyst Count
- GBTG 4
- AKRO 8
- Target Price
- GBTG $9.88
- AKRO $80.38
- AVG Volume (30 Days)
- GBTG 887.8K
- AKRO 915.6K
- Earning Date
- GBTG 11-04-2025
- AKRO 11-07-2025
- Dividend Yield
- GBTG N/A
- AKRO N/A
- EPS Growth
- GBTG N/A
- AKRO N/A
- EPS
- GBTG N/A
- AKRO N/A
- Revenue
- GBTG $2,440,000,000.00
- AKRO N/A
- Revenue This Year
- GBTG $4.46
- AKRO N/A
- Revenue Next Year
- GBTG $4.58
- AKRO N/A
- P/E Ratio
- GBTG N/A
- AKRO N/A
- Revenue Growth
- GBTG 3.61
- AKRO N/A
- 52 Week Low
- GBTG $5.78
- AKRO $21.34
- 52 Week High
- GBTG $9.60
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- GBTG 61.03
- AKRO 33.17
- Support Level
- GBTG $8.05
- AKRO $41.77
- Resistance Level
- GBTG $8.44
- AKRO $45.44
- Average True Range (ATR)
- GBTG 0.20
- AKRO 1.77
- MACD
- GBTG -0.05
- AKRO -0.22
- Stochastic Oscillator
- GBTG 68.75
- AKRO 5.66
About GBTG Global Business Travel Group Inc.
Global Business Travel Group Inc operates as a business-to-business travel platform. It is engaged in providing software and services to manage travel, expenses, and meetings and events for companies of all sizes. The company is engaged in building the marketplace in B2B travel to deliver unrivaled choice, value, and experiences. It also provides business travel solutions, simplified travel management, and business consulting services. Further, The company generates revenue in two ways that involves fees and other revenues relating to processing and servicing travel transactions received from clients and travel suppliers and revenues for the provision of products and professional services not directly related to transactions received from clients, travel suppliers and Network Partners.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.